We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Scientists Develop Implantable Telescope

By HospiMedica staff writers
Posted on 29 Aug 2007
Researchers are exploring the use of an implantable miniature telescope for use in end-stage age-related macular degeneration (AMD).

The Implantable Miniature Telescope (IMT) is designed to be a permanent solution for moderate to profound vision loss due to advanced, end-stage forms of AMD that have no current surgical or medical treatment options. More...
Smaller than a pea, the telescope prosthetic device is implanted in one eye in an outpatient surgical procedure. In the implanted eye, the device renders enlarged central vision images over a wide area of the retina to improve central vision, while the non-operated eye provides peripheral vision for mobility and orientation.

A prospective, multi-center phase II/III trial to evaluate the safety and efficacy of the IMT in individuals with moderate to profound bilateral central vision impairment enrolled over 200 patients at 28 leading medical universities and ophthalmic centers across the United States. The IMT was invented by VisionCare Ophthalmic Technologies (Saratoga, CA, USA). VisionCare has filed a pre-market approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the telescope prosthesis. The surgical procedure for implantation of the IMT was developed at the Massachusetts Eye and Ear Infirmary (MEEI; Boston, USA; www.meei.harvard.edu), and was described in the August 2007 issue of the Archives of Ophthalmology.

"What the telescope does is by enlarging the image the patient image is looking at, it allows them to see around these scotoma, or holes in their vision,” said lead author Kathryn Colby, M.D., Ph.D., director of the Joint Clinical Research Center (JCRC) at the MEEI.

Age-related macular degeneration is a group of conditions that include deterioration of the macula, resulting in loss of sharp central vision. Two general types: dry, which is more common, and wet, in which abnormal new blood vessels grow under the retina and leak fluid and blood (neovascularization), further disturbing macular function. AMD is the most common cause of decreased vision after age 60.


Related Links:
Massachusetts Eye and Ear Infirmary
VisionCare Ophthalmic Technologies

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.